


WHAT IS CLAIMED IS:

Claim 1. A unit dosage form for oral administration, wherein the unit dosage form comprises a hard gelatin capsule containing a composition, the composition comprising: Compound I, (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone:



in an amount of about 18.75% (w/w);

polyethylene glycol having a molecular weight of about 400 Daltons (PEG400), in an amount of about 6.5% (w/w); and

Vitamin E polyethylene glycol succinate (Vitamin E TPGS), in an amount of about 74.75% (w/w).

Claim 2. The unit dosage form of claim 1, wherein Compound I is present in an amount of from about 50 to about 150 mg.

Claim 3. The unit dosage form of claim 1 or 2, wherein the composition comprises:

Compound I, in an amount of about 50 mg;

PEG400, in an amount of about 17 mg; and

Vitamin E TPGS, in an amount of about 199 mg.

Claim 4. The unit dosage form of claim 1 or 2, wherein the composition comprises:

Compound I, in an amount of about 75 mg;

PEG400, in an amount of about 26 mg; and

Vitamin E TPGS, in an amount of about 299 mg.

Claim 5. The unit dosage form of claim 1 or 2, wherein the composition comprises: Compound I, in an amount of about 100 mg;

PEG400, in an amount of about 35 mg; and

Vitamin E TPGS, in an amount of about 399 mg.

Claim 6. The unit dosage form of claim 1 or 2, wherein the composition comprises:
Compound I, in an amount of about 150 mg;

PEG400, in an amount of about 52 mg; and

Vitamin E TPGS, in an amount of about 598 mg.

Claim 7. The unit dosage form of claim 1 or 2, wherein the composition consists essentially of:

Compound I, in an amount of 50 mg;

PEG400, in an amount of 17 mg; and

Vitamin E TPGS, in an amount of 199 mg.

Claim 8. The unit dosage form of claim 1 or 2 wherein the composition consists essentially of:

Compound I, in an amount of 75 mg;

PEG400, in an amount of 26 mg; and

Vitamin E TPGS, in an amount of 299 mg.

Claim 9. The unit dosage form of claim 1 or 2, wherein the composition consists essentially of:

Compound I, in an amount of 100 mg;

PEG400, in an amount of 35 mg; and

Vitamin E TPGS, in an amount of 399 mg.

Claim 10. The unit dosage form of claim 1 or 2, wherein the composition consists essentially of:

Compound I, in an amount of 150 mg;

PEG400, in an amount of 52 mg; and

Vitamin E TPGS, in an amount of 598 mg.

Claim 11. A unit dosage form of any one of claims 1 to 10, for use in treating the disorder or condition through modulating a glucocorticoid receptor.

Claim 12. A unit dosage form of any one of claims 1 to 10, for use in treating the disorder or condition through antagonizing a glucocorticoid receptor.

Claim 13. A unit dosage form of any one of claims 1 to 10, for use in treating amyotrophic lateral sclerosis (ALS).

Claim 14. A unit dosage form of any one of claims 1 to 10, for use in treating Alzheimer's disease.

Claim 15. A unit dosage form of any one of claims 1 to 10, for use in treating Huntington's disease.

Claim 16. Use of the composition of any one of claims 1 to 10 for the manufacture of a medicament for the treatment of a disorder or condition through modulating a glucocorticoid receptor.

Claim 17. Use of the composition of any one of claims 1 to 10 for the manufacture of a medicament for the treatment of a disorder or condition through antagonizing a glucocorticoid receptor.

Claim 18. Use of the composition of any one of claims 1 to 10 for the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis (ALS).

Claim 19. Use of the composition of any one of claims 1 to 10 for the manufacture of a medicament for the treatment of Alzheimer's disease.

Claim 20. Use of the composition of any one of claims 1 to 10 for the manufacture of a medicament for the treatment of Huntington's disease.